Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer
Future Oncology · 2023
DOI: 10.2217/fon-2023-0097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Tadayoshi Hashimoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Chemotherapy plus antiangiogenic agents, including bevacizumab, ramucirumab and aflibercept, is a standard second-line treatment for patients with metastatic colorectal cancer, but which specific agents should be selected is ambiguous due to a lack of clear evidence from prospective studies. Previous reports have suggested ramucirumab and aflibercept could be more effective than bevacizumab in patients with high VEGF-D and high VEGF-A, respectively. JCOG2004 is a three-arm, randomized, phase II study to identify predictive biomarkers for these agents in patients who have failed first-line treatment. The study will enroll 345 patients from 52 institutions for 2 years, with progression-free survival in high VEGF-D (bevacizumab vs ramucirumab) and high VEGF-A (bevacizumab vs aflibercept) serving as the primary end point. Clinical Trial Registration: jRCTs031220058 (www.jrct.niph.go.jp).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology & Hematology, Oita University Faculty of Medicine, Yufu, Japan.
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
ORCID-Profile: Tadayoshi Hashimoto
Zitieren
APA
Hashimoto, T., Otsu, S., Hironaka, S., Takashima, A., Mizusawa, J., Kataoka, T., Fukuda, H., Tsukamoto, S., Hamaguchi, T., & Kanemitsu, Y. (2023). Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0097
Vancouver
Hashimoto T, Otsu S, Hironaka S, Takashima A, Mizusawa J, Kataoka T, et al. Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. 2023. doi:10.2217/fon-2023-0097
BibTeX
@article{Hashimoto2023,
author = {Hashimoto, Tadayoshi and Otsu, Satoshi and Hironaka, Shuichi and Takashima, Atsuo and Mizusawa, Junki and Kataoka, Tomoko and Fukuda, Haruhiko and Tsukamoto, Shunsuke and Hamaguchi, Tetsuya and Kanemitsu, Yukihide},
title = {Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2023-0097}
}
EUVIMED